Toll Free: 1-888-928-9744

Schizophrenia - Pipeline Review, H1 2016

Published: May 31, 2016 | Pages: 435 | Publisher: Global Markets Direct | Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Schizophrenia - Pipeline Review, H1 2016

Summary

Global Markets Direct's, 'Schizophrenia - Pipeline Review, H1 2016', provides an overview of the Schizophrenia pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Schizophrenia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Schizophrenia and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Schizophrenia
- The report reviews pipeline therapeutics for Schizophrenia by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Schizophrenia therapeutics and enlists all their major and minor projects
- The report assesses Schizophrenia therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Schizophrenia


Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Schizophrenia
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Schizophrenia pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 6 Schizophrenia Overview 7 Therapeutics Development 8 Schizophrenia - Therapeutics under Development by Companies 10 Schizophrenia - Therapeutics under Investigation by Universities/Institutes 17 Schizophrenia - Pipeline Products Glance 18 Schizophrenia - Products under Development by Companies 22 Schizophrenia - Products under Investigation by Universities/Institutes 32 Schizophrenia - Companies Involved in Therapeutics Development 33 Schizophrenia - Therapeutics Assessment 112 Drug Profiles 129 Schizophrenia - Recent Pipeline Updates 329 Schizophrenia - Dormant Projects 387 Schizophrenia - Discontinued Products 402 Schizophrenia - Product Development Milestones 408 Appendix 416
List of Tables
Number of Products under Development for Schizophrenia, H1 2016 26 Number of Products under Development for Schizophrenia - Comparative Analysis, H1 2016 27 Number of Products under Development by Companies, H1 2016 29 Number of Products under Development by Companies, H1 2016 (Contd..1) 30 Number of Products under Development by Companies, H1 2016 (Contd..2) 31 Number of Products under Development by Companies, H1 2016 (Contd..3) 32 Number of Products under Development by Companies, H1 2016 (Contd..4) 33 Number of Products under Development by Companies, H1 2016 (Contd..5) 34 Number of Products under Investigation by Universities/Institutes, H1 2016 35 Comparative Analysis by Late Stage Development, H1 2016 36 Comparative Analysis by Clinical Stage Development, H1 2016 37 Comparative Analysis by Early Stage Development, H1 2016 38 Comparative Analysis by Unknown Stage Development, H1 2016 39 Products under Development by Companies, H1 2016 40 Products under Development by Companies, H1 2016 (Contd..1) 41 Products under Development by Companies, H1 2016 (Contd..2) 42 Products under Development by Companies, H1 2016 (Contd..3) 43 Products under Development by Companies, H1 2016 (Contd..4) 44 Products under Development by Companies, H1 2016 (Contd..5) 45 Products under Development by Companies, H1 2016 (Contd..6) 46 Products under Development by Companies, H1 2016 (Contd..7) 47 Products under Development by Companies, H1 2016 (Contd..8) 48 Products under Development by Companies, H1 2016 (Contd..9) 49 Products under Investigation by Universities/Institutes, H1 2016 50 Schizophrenia - Pipeline by AbbVie Inc., H1 2016 51 Schizophrenia - Pipeline by Acadia Pharmaceuticals Inc., H1 2016 52 Schizophrenia - Pipeline by Aequus Pharmaceuticals Inc., H1 2016 53 Schizophrenia - Pipeline by Aestus Therapeutics, Inc., H1 2016 54 Schizophrenia - Pipeline by AgeneBio Inc., H1 2016 55 Schizophrenia - Pipeline by Alkermes Plc, H1 2016 56 Schizophrenia - Pipeline by Amarantus Bioscience Holdings, Inc., H1 2016 57 Schizophrenia - Pipeline by Amgen Inc., H1 2016 58 Schizophrenia - Pipeline by Angita B.V., H1 2016 59 Schizophrenia - Pipeline by Astellas Pharma Inc., H1 2016 60 Schizophrenia - Pipeline by AstraZeneca Plc, H1 2016 61 Schizophrenia - Pipeline by Athersys, Inc., H1 2016 62 Schizophrenia - Pipeline by Avineuro Pharmaceuticals, Inc., H1 2016 63 Schizophrenia - Pipeline by BCWorld Pharm Co. Ltd., H1 2016 64 Schizophrenia - Pipeline by BioCrea GmbH, H1 2016 65 Schizophrenia - Pipeline by Boehringer Ingelheim GmbH, H1 2016 66 Schizophrenia - Pipeline by Braeburn Pharmaceuticals, Inc., H1 2016 67 Schizophrenia - Pipeline by Bristol-Myers Squibb Company, H1 2016 68 Schizophrenia - Pipeline by Coronis Partners Ltd., H1 2016 69 Schizophrenia - Pipeline by Critical Pharmaceuticals Limited, H1 2016 70 Schizophrenia - Pipeline by Curemark, LLC, H1 2016 71 Schizophrenia - Pipeline by Delpor, Inc., H1 2016 72 Schizophrenia - Pipeline by Echo Pharmaceuticals B.V., H1 2016 73 Schizophrenia - Pipeline by Egis Gyogyszergyar Nyrt, H1 2016 74 Schizophrenia - Pipeline by Eli Lilly and Company, H1 2016 75 Schizophrenia - Pipeline by Evotec AG, H1 2016 76 Schizophrenia - Pipeline by F. Hoffmann-La Roche Ltd., H1 2016 77 Schizophrenia - Pipeline by FORUM Pharmaceuticals Inc., H1 2016 78 Schizophrenia - Pipeline by Galenea Corp., H1 2016 79 Schizophrenia - Pipeline by GeNeuro SA, H1 2016 80 Schizophrenia - Pipeline by Gilead Sciences, Inc., H1 2016 81 Schizophrenia - Pipeline by Glenmark Pharmaceuticals Ltd., H1 2016 82 Schizophrenia - Pipeline by GP Pharm, S.A., H1 2016 83 Schizophrenia - Pipeline by GW Pharmaceuticals Plc, H1 2016 84 Schizophrenia - Pipeline by H. Lundbeck A/S, H1 2016 85 Schizophrenia - Pipeline by Heptares Therapeutics Limited, H1 2016 86 Schizophrenia - Pipeline by Hisamitsu Pharmaceutical Co., Inc., H1 2016 87 Schizophrenia - Pipeline by Indivior Plc, H1 2016 88 Schizophrenia - Pipeline by INSYS Therapeutics, Inc., H1 2016 89 Schizophrenia - Pipeline by Integrative Research Laboratories Sweden AB, H1 2016 90 Schizophrenia - Pipeline by IntelGenx Corp., H1 2016 91 Schizophrenia - Pipeline by Intra-Cellular Therapies, Inc., H1 2016 92 Schizophrenia - Pipeline by Iproteos S.L., H1 2016 93 Schizophrenia - Pipeline by Jiangsu Nhwa Pharmaceutical Corporation Ltd., H1 2016 94 Schizophrenia - Pipeline by Johnson & Johnson, H1 2016 95 Schizophrenia - Pipeline by Karuna Pharmaceuticals Inc., H1 2016 96 Schizophrenia - Pipeline by KemPharm, Inc., H1 2016 97 Schizophrenia - Pipeline by Laboratorios Farmaceuticos Rovi, S.A., H1 2016 98 Schizophrenia - Pipeline by Lead Discovery Center GmbH, H1 2016 99 Schizophrenia - Pipeline by Lohocla Research Corporation, H1 2016 100 Schizophrenia - Pipeline by Luc Therapeutics, Inc., H1 2016 101 Schizophrenia - Pipeline by Luye Pharma Group Ltd., H1 2016 102 Schizophrenia - Pipeline by Mapi Pharma Ltd., H1 2016 103 Schizophrenia - Pipeline by Merck & Co., Inc., H1 2016 104 Schizophrenia - Pipeline by Mitsubishi Tanabe Pharma Corporation, H1 2016 105 Schizophrenia - Pipeline by Neuralstem, Inc., H1 2016 106 Schizophrenia - Pipeline by Neurocrine Biosciences, Inc., H1 2016 107 Schizophrenia - Pipeline by NeurOp, Inc, H1 2016 108 Schizophrenia - Pipeline by Newron Pharmaceuticals S.p.A., H1 2016 109 Schizophrenia - Pipeline by Omeros Corporation, H1 2016 110 Schizophrenia - Pipeline by Otsuka Holdings Co., Ltd., H1 2016 111 Schizophrenia - Pipeline by Peptron, Inc., H1 2016 112 Schizophrenia - Pipeline by Pfizer Inc., H1 2016 113 Schizophrenia - Pipeline by Promentis Pharmaceuticals, Inc., H1 2016 114 Schizophrenia - Pipeline by Reviva Pharmaceuticals Inc., H1 2016 115 Schizophrenia - Pipeline by Richter Gedeon Nyrt., H1 2016 116 Schizophrenia - Pipeline by Saniona AB, H1 2016 117 Schizophrenia - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016 118 Schizophrenia - Pipeline by Spherium Biomed S.L., H1 2016 119 Schizophrenia - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H1 2016 120 Schizophrenia - Pipeline by Sunovion Pharmaceuticals Inc., H1 2016 121 Schizophrenia - Pipeline by Suven Life Sciences Ltd., H1 2016 122 Schizophrenia - Pipeline by Taisho Pharmaceutical Holdings Co., Ltd., H1 2016 123 Schizophrenia - Pipeline by Takeda Pharmaceutical Company Limited, H1 2016 124 Schizophrenia - Pipeline by Tetra Discovery Partners LLC, H1 2016 125 Schizophrenia - Pipeline by Teva Pharmaceutical Industries Ltd., H1 2016 126 Schizophrenia - Pipeline by Vanda Pharmaceuticals Inc., H1 2016 127 Schizophrenia - Pipeline by Zogenix, Inc., H1 2016 128 Schizophrenia - Pipeline by Zysis Limited, H1 2016 129 Assessment by Monotherapy Products, H1 2016 130 Assessment by Combination Products, H1 2016 131 Number of Products by Stage and Target, H1 2016 133 Number of Products by Stage and Mechanism of Action, H1 2016 139 Number of Products by Stage and Route of Administration, H1 2016 144 Number of Products by Stage and Molecule Type, H1 2016 146 Schizophrenia Therapeutics - Recent Pipeline Updates, H1 2016 347 Schizophrenia - Dormant Projects, H1 2016 405 Schizophrenia - Dormant Projects (Contd..1), H1 2016 406 Schizophrenia - Dormant Projects (Contd..2), H1 2016 407 Schizophrenia - Dormant Projects (Contd..3), H1 2016 408 Schizophrenia - Dormant Projects (Contd..4), H1 2016 409 Schizophrenia - Dormant Projects (Contd..5), H1 2016 410 Schizophrenia - Dormant Projects (Contd..6), H1 2016 411 Schizophrenia - Dormant Projects (Contd..7), H1 2016 412 Schizophrenia - Dormant Projects (Contd..8), H1 2016 413 Schizophrenia - Dormant Projects (Contd..9), H1 2016 414 Schizophrenia - Dormant Projects (Contd..10), H1 2016 415 Schizophrenia - Dormant Projects (Contd..11), H1 2016 416 Schizophrenia - Dormant Projects (Contd..12), H1 2016 417 Schizophrenia - Dormant Projects (Contd..13), H1 2016 418 Schizophrenia - Dormant Projects (Contd..14), H1 2016 419 Schizophrenia - Discontinued Products, H1 2016 420 Schizophrenia - Discontinued Products (Contd..1), H1 2016 421 Schizophrenia - Discontinued Products (Contd..2), H1 2016 422 Schizophrenia - Discontinued Products (Contd..3), H1 2016 423 Schizophrenia - Discontinued Products (Contd..4), H1 2016 424 Schizophrenia - Discontinued Products (Contd..5), H1 2016 425


List of Figures
Number of Products under Development for Schizophrenia, H1 2016 26 Number of Products under Development for Schizophrenia - Comparative Analysis, H1 2016 27 Number of Products under Development by Companies, H1 2016 28 Number of Products under Investigation by Universities/Institutes, H1 2016 35 Comparative Analysis by Late Stage Development, H1 2016 36 Comparative Analysis by Clinical Stage Development, H1 2016 37 Comparative Analysis by Early Stage Products, H1 2016 38 Assessment by Monotherapy Products, H1 2016 130 Assessment by Combination Products, H1 2016 131 Number of Products by Top 10 Targets, H1 2016 132 Number of Products by Stage and Top 10 Targets, H1 2016 132 Number of Products by Top 10 Mechanism of Actions, H1 2016 138 Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016 138 Number of Products by Routes of Administration, H1 2016 143 Number of Products by Stage and Routes of Administration, H1 2016 143 Number of Products by Molecule Types, H1 2016 145 Number of Products by Stage and Molecule Types, H1 2016 145

To request a free sample copy of this report, please complete the form below.

This website is secure and your personal details are safe. Privacy policy

Global contact lenses market size is estimated to reach USD 12.5 billion by 2020, according to a new industry report by Radiant Insights, Inc. Growing number of ophthalmic disorder observed in global population especially children is likely to drive

Read More...

North America air conditioner market size is expected to be valued at USD 52,560.7 million by 2020, as per a new research report by Radiant Insights, Inc. Increasing usage of energy efficient air conditioners owing to declining energy consumption rat

Read More...

Global automotive electronics market size forecast is likely to reach USD 279.96 billion by 2020, as per a new research report by Radiant Insights, Inc. Growing application scope of these equipments is estimated to drive industry growth. Increasing i

Read More...

Global polymethyl methacrylate (PMMA) market size is likely to be valued at USD 11.65 billion by 2022; as per a new research report by Radiant Insights, Inc. Increasing spending on advertising & marketing for building strong brand equity and product

Read More...

Global integrated systems market is projected to reach USD 24 billion by 2020, as per a new research report by Radiant Insights, Inc. Increasing need to re-evaluate data center infrastructure is expected to boost the demand. Change in trend from main

Read More...
Choose License Type
Single User - US $2000
Multi User - US $4000
Why Choose Us

24/5 Research support

Get your queries resolved from an industry expert. Request for a free product review before report purchase.

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify